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Pyronaridine–artesunate or dihydroartemisinin–piperaquine 
versus current first-line therapies for repeated treatment of 
uncomplicated malaria: a randomised, multicentre, 
open-label, longitudinal, controlled, phase 3b/4 trial
The West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)*
Summary
Background Artemether–lumefantrine and artesunate–amodiaquine are used as first-line artemisinin-based 
combination therapies (ACTs) in west Africa. Pyronaridine–artesunate and dihydroartemisinin–piperaquine are 
potentially useful for diversification of ACTs in this region, but further safety and efficacy data are required on 
malaria retreatment.
Methods We did a randomised, multicentre, open-label, longitudinal, controlled phase 3b/4 clinical trial at seven tertiary 
centres in Burkina Faso, Guinea, and Mali. Eligible participants for first malaria episode and all retreatment episodes 
were adults and children aged 6 months and older with microscopically confirmed Plasmodium spp malaria (>0 to 
<200 000 parasites per µL of blood) and fever or history of fever in the previous 24 h. Individuals with severe or 
complicated malaria, an alanine aminotransferase concentration of more than twice the upper limit of normal, or a QTc 
greater than 450 ms were excluded. Using a randomisation list for each site, masked using sealed envelopes, participants 
were assigned to either pyronaridine–artesunate or dihydroartemisinin–piperaquine versus either artesunate–
amodiaquine or artemether–lumefantrine. Block sizes were two or four if two treatments were allocated, and three or 
six if three treatments were allocated. Microscopists doing the parasitological assessments were masked to treatment 
allocation. All treatments were once-daily or twice-daily tablets or granules given orally and dosed by bodyweight over 
3 days at the study centre. Patients were followed up as outpatients up to day 42, receiving clinical assessments on days 
0, 1, 2, 3, 7, 14, 21, 28, 35, and 42. Two primary outcomes were compared for non-inferiority: the 2-year incidence rate of 
all microscopically confirmed, complicated and uncomplicated malaria episodes in patients in the intention-to-treat 
population (ITT; non-inferiority margin 20%); and adequate clinical and parasitological response (ACPR) in 
uncomplicated malaria across all episodes (unadjusted and PCR-adjusted for Plasmodium falciparum and unadjusted 
for other Plasmodium spp) in the per-protocol population on days 28 and 42 (non-inferiority margin 5%). Safety was 
assessed in all participants who received one dose of study drug. This study is registered at the Pan African Clinical 
Trials Registry (PACTR201105000286876).
Findings Between Oct 24, 2011, and Feb 1, 2016, we assigned 4710 eligible participants to the different treatment 
strategies: 1342 to pyronaridine–artesunate, 967 to artemether–lumefantrine, 1061 to artesunate–amodiaquine, and 
1340 to dihydroartemisinin–piperaquine. The 2-year malaria incidence rate in the ITT population was non-inferior 
for pyronaridine–artesunate versus artemether–lumefantrine (1·77, 95% CI 1·63–1·93 vs 1·87, 1·72–2·03; rate ratio 
[RR] 1·05, 95% CI 0·94–1·17); and versus artesunate–amodiaquine (1·39, 95% CI 1·22–1·59 vs 1·35, 1·18–1·54; 
RR 0·97, 0·87–1·07). Similarly, this endpoint was non-inferior for dihydroartemisinin–piperaquine versus 
artemether–lumefantrine (1·16, 95% CI 1·01–1·34 vs 1·42 1·25–1·62; RR 1·22, 95% CI 1·06–1·41) and versus 
artesunate–amodiaquine (1·35, 1·21–1·51 vs 1·68, 1·51–1·88; RR 1·25, 1·02–1·50). For uncomplicated P falciparum 
malaria, PCR-adjusted ACPR was greater than 99·5% at day 28 and greater than 98·6% at day 42 for all ACTs; 
unadjusted ACPR was higher for pyronaridine–artesunate versus comparators at day 28 (96·9% vs 82·3% for 
artemether–lumefantrine and 95·6% vs 89·0% for artesunate–amodiaquine) and for dihydroartemisinin-piperaquine 
versus comparators (99·5% vs 81·6% for artemether–lumefantrine and 99·0% vs 89·0% for artesunate–
amodiaquine). For non-falciparum species, unadjusted ACPR was greater than 98% for all study drugs at day 28 and 
at day 42 was greater than 83% except for artemether–lumefantrine against Plasmodium ovale (in ten [62·5%] of 
16 patients) and against Plasmodium malariae (in nine [75·0%] of 12 patients). Nine deaths occurred during the 
study, none of which were related to the study treatment. Mostly mild transient elevations in transaminases occurred 
with pyronaridine–artesunate versus comparators, and mild QTcF prolongation with dihydroartemisinin-piperaquine 
versus comparators.
Interpretation Pyronaridine–artesunate and dihydroartemisinin–piperaquine treatment and retreatment of malaria 
were well tolerated with efficacy that was non-inferior to first-line ACTs. Greater access to these efficacious treatments 
in west Africa is justified.
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Introduction
In west Africa, 355 million people are at risk of malaria, 
with an estimated 112 million cases and 218 000 deaths 
occurring annually.1 Artemisinin-based combination 
therapy (ACT) is recommended for uncomplicated 
Plasmodium falciparum malaria.2 Because at-risk 
individuals might have frequent malaria episodes 
throughout their lives, ACTs must be assessed on repeated 
treatments. Artemether–lumefantrine and artesunate–
amodiaquine were adopted as first-line ACTs in west Africa 
following studies showing retreatment efficacy and 
acceptable safety.3–7 Artesunate–amodiaquine for malaria 
treatment is currently discouraged for children 
aged 3–59 months in the Sahelian countries in Africa that 
have adopted seasonal malaria chemoprevention with 
sulfadoxine–pyrimethamine plus amodiaquine.1,8 Thus, 
artemether–lumefantrine is the only ACT available for 
malaria treatment across much of west Africa.
Two more recently licensed ACTs—pyronaridine–
artesunate9–14 and dihydroartemisinin–piperaquine15–22—
showed high efficacy and were well tolerated in randomised 
clinical trials. Both are prequalified by WHO and included 
in WHO’s Essential Medicines List, and would potentially 
be useful for ACT diversification in sub-Saharan Africa. 
However, a higher incidence of non-symptomatic increases 
in hepatic transaminase concentrations has been noted 
with pyronaridine–artesunate versus comparator drugs.2,9,23 
Further data are needed to characterise the risk for 
hepatotoxicity, particularly in young children, and whether 
there is an increased risk after retreatment for malaria. 
Dihydroartemisinin–piperaquine is used extensively in 
Asia but less so in Africa. Piperaquine prolongs the QT 
interval by approximately the same amount as chloroquine24 
and further safety data on the retreatment risk of QT 
prolongation with piperaquine in African populations 
would be valuable. Dihydroartemisinin–piperaquine has 
been shown to reduce the risk of recurrent malaria versus 
artemether–lumefantrine.25,26 However, the longitudinal 
effect on malaria incidence has not been investigated.
Therefore we undertook the West African Network for 
Clinical Trials of Antimalarial Drugs (WANECAM) 
longitudinal study to assess malaria incidence and 
pyronaridine–artesunate or dihydroartemisinin–piper-
aquine efficacy and safety when used repeatedly for 
consecutive clinical malaria episodes over a 2-year period, 
compared with artemether–lumefantrine or artesunate–
amodiaquine. A smaller substudy of pyronaridine–
artesunate hepatic safety after repeated treatment 
compared with artemether–lumefantrine over 12 months’ 
follow-up has been published.14 This report is on the 
complete 2-year follow-up period across all enrolled 
patients, malaria episodes, and treatment arms.
Research in context
Evidence before this study
Artemisinin-based combination therapy (ACT) is 
recommended for treatment of uncomplicated Plasmodium 
falciparum malaria. In west Africa, people often have repeated 
episodes of malaria and therefore ACTs should be safe and 
effective for malaria retreatment. In this region, 
artemether–lumefantrine and artesunate–amodiaquine were 
adopted as first-line ACTs, following studies showing they had 
retreatment efficacy and acceptable safety. 
Pyronaridine–artesunate and dihydroartemisinin–piperaquine 
are more recently approved ACTs that have shown high 
efficacy and acceptable safety in randomised clinical trials. 
However, data are needed regarding efficacy and safety for 
malaria retreatment.
Added value of this study
The 2-year incidence of malaria in the intention-to-treat 
population in three countries in west Africa was non-inferior for 
pyronaridine–artesunate or dihydroartemisinin–piperaquine 
versus comparators. Our study provides evidence of the efficacy 
and safety of pyronaridine–artesunate and dihydroartemisinin–
piperaquine for the repeated treatment of malaria in this 
African population.
Implications of all the available evidence
At present, only artemether–lumefantrine and 
artesunate–amodiaquine are available for first-line treatment 
of malaria in west Africa. Recently, artesunate–amodiaquine 
use has become restricted in most of west Africa because of the 
adoption of seasonal malaria chemoprevention with 
sulfadoxine–pyrimethamine plus amodiaquine. This study 
supports the wider use of pyronaridine–artesunate and 
dihydroartemisinin–piperaquine in west Africa, which is a key 
development for health care in the region and provides new 
options for national malaria control programmes when 
planning malaria treatment strategies.
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National de Formation et de Recherche en Santé Rurale (Republic of Guinea).
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
For WHO’s Essential Medicines 
List see http://www.who.int/
medicines/publications/
essentialmedicines/en/
Articles
1380 www.thelancet.com   Vol 391   April 7, 2018
Methods
Study design and participants
We undertook a phase 3b/4 comparative, randomised, 
multicentre, open-label, longitudinal clinical study 
over 2 years at seven tertiary centres in Burkina Faso 
(Bobo Dioulasso and Banfora-Niangoloko), Guinea 
(Maferenya), and Mali (Bougoula-Hameau, Djoliba, 
Kolle, and Sotuba). Ethical approval was obtained from 
local ethics committees for each site. The WANECAM 
study protocol version 12 (eight amendments) is 
available online. All protocol amendments are in 
the appendix.
Eligible participants were adults and children 
aged 6 months and older of either sex with uncomplicated 
malaria and a bodyweight of at least 5 kg, with no clinical 
evidence of severe malnutrition. For the first 40 patients 
retreated with pyronaridine–artesunate (and comparators), 
enrolment was staged for bodyweight and age based on a 
review by a data safety monitoring board (appendix). For 
the first malaria episode and all retreatment episodes, 
eligibility criteria were fever (axillary temperature ≥37·5°C, 
or oral, or rectal, or tympanic temperature ≥38°C) or 
history of fever in the previous 24 h, and positive 
microscopy for Plasmodium spp (>0 to <200 000 parasites 
per µL of blood). All participants had to be able to swallow 
oral medication and remain in the study vicinity with no 
absence of more than 3 months. 
Exclusion criteria for the first malaria episode were 
severe or complicated malaria, severe vomiting or 
diarrhoea, known history or evidence of any clini-
cally significant disorders, a QTc value of more than 
450 ms, haemoglobin of less than 7 g/dL, non-malarial 
febrile conditions, known drug hypersensitivity, anti-
malarial treatment within the previous 2 weeks or an 
investi gational drug within 4 weeks, known or sus-
pected alcohol abuse, known HIV-antibody positivity, 
hep atitis A IgM, hepatitis B surface antigen or 
hepatitis C antibody, alanine aminotransferase (ALT) 
concentration of more than twice the upper limit 
of normal (ULN), or significant renal impairment 
(creatinine >1·5 × ULN). Pregnant or lactating women 
were excluded, and women aged 12 years and older 
required a negative pregnancy test and could not be 
planning a pregnancy during each 42-day period after 
treatment. All participants or their parent or guardian 
provided written informed consent, plus children able 
to understand the study gave assent.
For each retreatment episode, exclusion criteria were 
severe or complicated malaria, severe vomiting or 
diarrhoea, liver function test result of more than twice 
the ULN, significant arrhythmia or prolonged QTc of 
more than 450 ms during previous treatment or at 
presentation, active acute hepatitis A, B, or C, renal 
impairment (creatinine >1·5 × ULN), an ongoing severe 
adverse event not related to study drug, parasite relapse 
before day 28, use of any other antimalarial drug, 
pregnancy, or breastfeeding.
Randomisation and masking
We assigned eligible participants to repeated therapy 
with either pyronaridine–artesunate (Shin Poong 
Pharma ceutical, Ansan, South Korea) or dihydro-
artemisinin–piperaquine (Alfasigma SpA, Pomezia, [RM], 
Italy) versus either artemether–lumefantrine (Novartis 
Pharma AG, Basel, Switzerland) or artesunate–
amodiaquine (Sanofi, Paris, France), depending on study 
centre. There was no direct comparison between 
pyronaridine–artesunate and dihydroartemisinin–piper-
aquine. This was an open label study, although 
microscopists doing the parasitological assessments were 
masked to treatment allocation. A computer-generated 
randomisation list for each site within each country was 
used. To minimise the risk of investigators guessing 
treatment allocation, when there were two treatments to 
allocate the block size was randomly two or four and when 
there were three treatments to allocate the block size was 
randomly three or six. The University of Bamako data 
management team enclosed the randomisation code 
containing the study arm in sealed, opaque, sequentially 
numbered envelopes. The site investigator opened the 
envelopes in order and assigned treatment accordingly. 
Because recruitment criteria for age and bodyweight 
differed between treat ments, a separate randomisation list 
was generated for each experimental drug.
Procedures
All treatments were dosed according to bodyweight 
(appendix). The following procedures were undertaken for 
every malaria episode: patients eligible for treatment were 
administered an ACT once daily (twice daily for artemether–
lumefantrine; appendix). Adults received tablets with water 
and young children received pyronaridine–artesunate 
granules, artemether–lumefantrine dispersible tablets, 
dissolved artesunate–amodiaquine tablets or crushed 
dihydroartemisinin–piperaquine tablets, all given in water. 
There were no requirements or restrictions regarding food 
intake. Patients were treated as inpatients on days 1 to 3 and 
followed up as outpatients until day 42, except in Bougoula-
Hameau (63 days’ follow-up, data not shown). Clinical 
assessments were done on days 0, 1, 2, 3, 7, 14, 21, 28, 
35, and 42.
Patients with symptomatic parasitaemia at or after the 
day 28 visit were retreated with the ACT allocated at initial 
randomisation. For treatment failure before day 28, or if 
inclusion or exclusion criteria were not met for that 
episode, alternative rescue therapy was given. At the 
screening visit, a physical examination was done and a 
medical history was taken. Asexual parasites and 
gametocytes were identified and enumerated using 
standard protocols.14,27 For parasite evaluation, we obtained 
blood samples at the start of each treatment episode, then 
every 12 h (range 10–14) up to 72 h or until two consecutive 
blood smears were parasite-negative, and at days 7, 14, 21, 
28, 35, 42 at the time of withdrawal or if malaria was 
suspected. Slides were read by two qualified microscopists, 
For the WANECAM study 
protocol see www.wanecam.org
See Online for appendix
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masked to treatment allocation, with any discordant results 
read by a third reader whose results were then accepted. 
Blood spots for P falciparum PCR genotyping were 
obtained at the same time as blood smears. P falciparum 
recrudescence was distinguished from reinfection using 
msp1, msp2, and microsatellite markers.3,28
Adverse events were assessed every 12 h after treatment 
start until 72 h and at all follow-up visits. Clinical chemistry 
and haematology samples were collected pretreatment on 
day 0, 72 h after treatment start (after the final dose), 
days 7 and 28, and at other times if hepatic tests were 
abnormal or if deemed necessary by the investigator. 
Digital 12-lead electrocardiographs were done on 
day 0 (pre-dose), day 2 (post-dose), and day 3 if clinically 
indicated. Criteria for permanent drug discontinuation 
were a drug-related serious adverse event, study drug 
hypersensitivity, drug-related QTc prolongation greater 
than 450 ms, active or chronic hepatitis B or C, known 
HIV antibody positivity, ALT greater than five times ULN 
(revised to >8 × ULN, implemented at protocol version 12.0), 
Hy’s criteria (ALT or aspartate aminotransferase [AST] 
>3 × ULN and total bilirubin >2 × ULN), travel outside the 
study area for more than 3 months, consent withdrawal, 
or any medical condition considered to jeopardise 
patient safety.
Outcomes
The two primary efficacy outcomes were (1) the 2-year 
incidence rate of all repeat malaria episodes (un-
complicated and complicated) irrespective of parasite 
species; and (2) the unadjusted and PCR-adjusted adequate 
clinical and parasitological response (ACPR) for 
P falciparum and unadjusted ACPR for other Plasmodium 
species (ie, P ovale and P malariae) at days 28 and 42. ACPR 
was defined as the absence of microscopically detectable 
parasitaemia until day 28 or 42, irrespective of axillary 
temperature, without previous early treatment failure, late 
clinical failure, or late parasitological failure.27 PCR-
adjusted treatment success excluded malaria episodes 
caused by PCR-confirmed P falciparum reinfection.27,28
Secondary endpoints were reinfection and recrudescence 
rates over 42 days, parasite clearance time (time from first 
dose until parasite negative, maintained for 48 h), 
gametocyte density and carriage, the difference in time to 
the second infection between treatments, and the 
difference in the mean interval between reinfections.
Safety outcomes were adverse event incidence and 
severity, coded using MedDRA (version 19.0), clinically 
significant laboratory results (hepatic safety criteria in 
appendix), changes in vital signs, potential QT or QTc 
interval prolongation and QTc change from baseline, and 
effects on the CNS.
Statistical analysis
For the primary efficacy endpoint of the all-malaria 
incidence rate over 2 years, we calculated the sample size 
based on the survival method,29 using an estimated malaria 
incidence rate of 3·29 episodes per person over 2 years 
in the comparator arm (artemether–lumefantrine or 
artesunate–amodiaquine).30 Assuming a non-inferiority 
margin of 20% for pyronaridine–artesunate or dihydro-
artemisinin–piperaquine versus control, a signifi cance 
level of 5%, a power of 80%, and loss to follow-up of 15%, a 
total sample size of 4032 patients was needed. To achieve a 
power of at least 80%, a sample size of 370 patients per 
treatment arm was required for each comparison. For 
the primary efficacy endpoint of ACPR, assuming a 
95% treatment success rate and 5% non-inferiority 
margin, we calculated that 4032 patients would pro-
vide 93% power. To achieve enough young children in the 
pyronaridine–artesunate arm, the recruitment target 
was increased to 4722 (1344 pyronaridine–artesunate, 
968 artemether–lumefantrine, 1066 artesunate–amodia-
quine, and 1344 dihydroartemisinin–piperaquine).
The safety population included all patients who 
received at least one dose of study therapy. The intention-
to-treat (ITT) population included patients in the safety 
population with a day 0 pre-dose positive Plasmodium 
spp parasite count. The per-protocol (PP) population 
included all patients who completed a full course of study 
medication for any treatment episode with valid efficacy 
outcomes on day 28 or day 42 for that episode.
All outcomes were evaluated for non-inferiority of 
pyronaridine–artesunate versus artemether–lumefantrine 
or artesunate–amodiaquine, and non-inferiority of 
dihydro artemisinin–piperaquine versus artemether–
lumefantrine or artesunate–amodiaquine. Because of the 
randomisation method, neither pyronaridine–artesunate 
versus dihydroartemisinin–piperaquine or artemether–
lumefantrine versus artesunate–amodiaquine were valid 
comparisons.
The 2-year incidence of uncomplicated and complicated 
repeat malaria episodes was calculated for the ITT 
population using a Poisson regression model done 
separately for each treatment comparison. In the case of 
overdispersion of data (ie, if the variance was greater 
than the mean), negative binomial regression analysis 
was used. Analysis of the PP population was not planned 
for this outcome, as the aim was to capture all repeat 
malaria episodes occurring in all patients who received 
treatment for the initial malaria episode.
Unadjusted and PCR-adjusted ACPR at days 28 and 42 
across all P falciparum uncomplicated malaria episodes 
was estimated using a generalised estimating equation 
(GEE) model with ACPR as a binary-dependent variable, 
randomised treatment group as a fixed effect, and the 
patient as a random effect.14 Treatment-group estimates 
and estimates for the treatment differences with their 
associated 95% CI were derived. The PP population was 
used for the primary analysis of non-inferiority in ACPR, 
and the ITT population as a supporting analysis for 
this outcome. For non-falciparum species, descriptive 
statistics of unadjusted ACPR at days 28 and 42 
by treatment episode were used. For both primary 
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Figure 1: Trial profile
Data for recruitment by centre and country, reasons for study withdrawal and treatment discontinuation, reasons for exclusion from the intention-to-treat population, and day 28 or 42 per-protocol 
populations for each malaria episode are in the appendix. ECG=electrocardiogram. PA=pyronaridine–artesunate. AL=artemether–lumefantrine. DP=dihydroartemisinin–piperaquine. 
ASAQ=artesunate–amodiaquine. 
7091 patients assessed for eligibility
2367 excluded
1013 no malaria
288 abnormal ECG
209 patient unsuitable (eg, because they could not return to the clinic for assessments)
117 no consent
144 anaemia or abnormal haematology
94 operational issues with the study
91 severe malaria
83 raised liver function test
328 other
Burkina Faso
448 received PA
296 received AL
315 received ASAQ
448 received DP
Randomised as:
72 PA versus 72 AL
91 PA versus 91 ASAQ
72 DP versus 72 AL
91 DP versus 91 ASAQ
152 PA or 152 DP versus 152 AL
133 PA or 133 DP versus 133 ASAQ 
Guinea
235 received PA
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Randomised as:
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PA versus AL PA versus ASAQ DP versus AL DP versus ASAQ
14 excluded because of an administrative issue
Mali
659 received PA
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583 received DP
Randomised as:
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224 DP versus 224 AL
224 DP versus 224 ASAQ
131 PA or 135 DP versus 132 ASAQ 
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endpoints, planned subanalyses were done based on 
country, age category, and bodyweight category.
All secondary efficacy outcomes were assessed in the 
ITT population. Recurrence rates for each Plasmodium 
species and recrudescence or reinfection rates for 
P falciparum over 42 days were calculated using 
Kaplan-Meier survival analysis, adjusted for repeated 
measures as appropriate. Patients were censored if they 
had an infection with another species than the one 
present at baseline, if they received a prohibited 
concomitant medication, if they did not receive the full 
course of study medication, or if they completed the 
study or discontinued prematurely. The time between 
the first and the second uncomplicated malaria episodes 
and the time between each two uncomplicated malaria 
episodes was summarised with descriptive statistics. 
Parasite clearance time was summarised using 
Kaplan-Meier estimates by treatment episode. Patients 
with no parasite clearance and those who received 
rescue therapy before parasite clearance were censored. 
Gametocyte clearance time was analysed similarly. The 
number of patients with gametocytes and gametocyte 
density were summarised using descriptive statistics.
Safety outcomes were assessed in the safety population 
and analysed using descriptive statistics. Statistical 
analyses used SAS (version 9.3). This study is registered 
at the Pan African Clinical Trials Registry, number 
PACTR201105000286876.
Role of the funding source
Authors associated with the funder of the study had a 
role in developing the protocol, study design, data 
collection, data analysis, data interpretation, and writing 
of the report. All authors had full access to all the data in 
the study and had final responsibility for the decision to 
submit for publication.
Results
Between Oct 24, 2011, and Feb 1, 2016, we randomly 
assigned 4710 eligible participants to treatment: 1342 to 
pyronaridine–artesunate, 967 to artemether–lumefantrine, 
1061 to artesunate–amodiaquine, and 1340 to dihydro-
artemisinin–piperaquine (figure 1). Nearly half of all 
randomly assigned patients were from Mali because of 
additional recruitment from this country while Guinea 
sites were closed during an epidemic of Ebola virus 
disease (figure 1, appendix). The possibility to recruit 
patients from other sites in the network had been included 
as a protocol amendment (appendix).
There were 326 withdrawals (7%) of 4710 patients 
throughout the study, with no major differences in the 
reason for withdrawal between the treatment comparisons 
(appendix). Reasons for exclusion from the PP population 
per malaria episode are also in the appendix. Baseline 
characteristics were similar between treatment com-
parisons (table 1). The 4710 patients included in the 
ITT population had 8640 repeat malaria episodes 
(7279 uncomplicated and 1361 complicated) over 2 years 
(appendix). 7119 episodes of repeated uncomplicated 
malaria was caused by P falciparum, 146 by P malariae, 
and 31 by P ovale, including 17 mixed infections.
For the primary outcome of repeat malaria (complicated 
and uncomplicated) incidence rate, because variance was 
greater than the mean we analysed data using negative 
binomial regression. The 2-year repeat malaria incidence 
rate (complicated and uncomplicated) in the ITT 
population was non-inferior for pyronaridine–artesunate 
versus artemether–lumefantrine (1·77, 95% CI 1·63–1·93 
vs 1·87, 1·72–2·03) and versus artesunate–amodiaquine 
(1·39, 95% CI 1·22–1·59 vs 1·35, 1·18–1·54; figure 2) and 
also non-inferior for dihydroartemisinin–piperaquine 
versus artemether–lumefantrine (1·16, 95% CI 
1·01–1·34 vs 1·42, 1·25–1·62) and versus artesunate–
amodiaquine (1·35, 95% CI 1·21–1·51 vs 1·68, 1·51–1·88; 
figure 2). Two-year Plasmodium spp malaria incidence 
rates were higher in Burkina Faso and Mali versus 
Guinea, in children younger than 5 years versus adults, 
and in those with bodyweight of 20 kg or less versus 
heavier than 20 kg across all treatment groups (appendix). 
The study was not powered for subgroup comparisons of 
non-inferiority, but upper 95% CIs for pyronaridine–
artesunate and dihydroartemisinin–piperaquine were 
greater than 1 for all comparisons based on country, age, 
and bodyweight (appendix).
In the PP population, PCR-adjusted or unadjusted 
ACPR estimated using a GEE model across all 
uncomplicated P falciparum episodes showed pyro-
naridine–artesunate to be non-inferior to artemether–
lumefantrine or artesunate–amodiaquine (figure 2); 
similarly dihydroartemisinin–piperaquine was non-
inferior to the two comparator ACTs (figure 2, appendix). 
All treatments met WHO efficacy criteria (>95% ACPR) 
for therapy adoption,2 with PCR-adjusted ACPR in the PP 
population at least 99·5% at day 28 and at least 98·6% at 
day 42 (appendix). High PCR-adjusted ACPR rates were 
maintained across countries, and age and bodyweight 
categories (appendix). High rates of PCR-adjusted ACPR 
in the PP population were also sustained across all 
malaria retreatment episodes (appendix).
Unadjusted ACPR rates in the PP population were 
higher with pyronaridine–artesunate and dihydro-
artemisinin–piperaquine versus comparators (figure 2, 
appendix). Unadjusted ACPR in the ITT population 
was also higher for pyronaridine–artesunate and 
dihydroartemisinin–piperaquine versus comparators 
at days 28 and 42 (appendix). For non-falciparum 
species, in the PP population unadjusted ACPR 
was greater than 98% for all study drugs at day 28 and at 
day 42 was greater than 83% except for artemether–
lumefantrine against P ovale (62·5%, 10/16) and 
P malariae (75·0%, 9/12; appendix).
Median time between any malaria episode was 
175·5 days (IQR 65·3–319·0) for pyronaridine–artesunate 
versus 154·8 (58·0–298·5) for artemether–lumefantrine; 
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162·0 days (59·0–285·0) for pyro naridine–artesunate 
versus 159·3 (62·0–269·5) for artesunate–amodiaquine; 
195·3 days (96·0–344·5) for dihydro artemisinin–
piperaquine versus 106·0 (47·0–307·0) for artemether–
lumefantrine; and 157·5 days (85·0–269·0) for 
artemisinin–piperaquine versus 115·0 (56·0–232·0) for 
artesunate–amodiaquine (appendix).
Kaplan-Meier analysis of the first malaria episode, 
indicated a lower recurrence rate with pyronaridine–
artesunate versus artemether–lumefantrine (p<0·0001; 
figure 2), but not versus artesunate–amodiaquine 
(p=0·67); and with dihydroartemisinin–piperaquine 
versus both comparators (p=0·0001; figure 2). Further 
analysis showed a lower P falciparum reinfection risk with 
pyronaridine–artesunate versus artemether–lumefantrine 
(p<0·0001) but not versus artesunate–amodiaquine 
(p=0·62), and for dihydroartemisinin–piperaquine versus 
both comparators (p<0·0001) (appendix). The risk of 
recrudescence was similar between study drugs (p>0·06; 
appendix). 
Estimated across all uncomplicated malaria epi-
sodes, P falciparum parasite clearance time was slower with 
artemether–lumefantrine versus pyronaridine–artesunate 
(p<0·0001), and slower with artemether–lumefantrine 
versus dihydroartemisinin–piperaquine (p<0·0001; app-
endix). For the first episode, median parasite clearance 
time was 24·7 h (95% CI 24·3–26·1) with pyronaridine–
artesunate versus 34·5 h (34·2–35·1) for artemether–
lumefantrine (appendix). The proportion of patients with 
parasite clearance 24 h after the first dose was 253/665 
Pyronaridine–artesunate versus 
artemether–lumefantrine
Pyronaridine–artesunate versus 
artesunate–amodiaquine
Dihydroartemisinin–piperaquine 
versus artemether–lumefantrine
Dihydroartemisinin–piperaquine 
versus artesunate–amodiaquine
Pyronaridine–
artesunate 
(n=673)
Artemether–
lumefantrine 
(n=671)
Pyronaridine–
artesunate 
(n=669)
Artesunate–
amodiaquine 
(n=668)
Dihydroartemisinin–
piperaquine 
(n=448)
Artemether–
lumefantrine 
(n=448)
Dihydroartemisinin–
piperaquine 
(n=892)
Artesunate–
amodiaquine 
(n=891)
Country
Burkina Faso 224 (33%) 224 (33%) 224 (33%) 224 (34%) 224 (50%) 224 (50%) 224 (25%) 224 (25%)
Guinea 0 0 235 (35%) 233 (35%) 0 0 309 (35%) 311 (35%)
Mali 449 (67%) 447 (67%) 210 (31%) 211 (32%) 224 (50%) 224 (50%) 359 (40%) 356 (40%)
Female sex 328 (49%) 319 (48%) 350 (52%) 308 (46%) 219 (49%) 224 (50%) 427 (48%) 413 (46%)
Age (years) 11·8 (9·4) 11·7 (9·6) 7·3 (5·5) 7·0 (5·7) 9·6 (7·9) 9·1 (7·1) 7·6 (5·2) 7·5 (5·2)
Age group (years)
<5 116 (17%) 129 (19%) 228 (34%) 249 (37%) 85 (19%) 102 (23%) 256 (29%) 264 (30%)
≥5 to <15 371 (55%) 341 (51%) 402 (60%) 386 (58%) 320 (71%) 299 (67%) 585 (66%) 589 (66%)
≥15 186 (28%) 201 (30%) 39 (6%) 33 (5%) 43 (10%) 47 (10%) 51 (6%) 38 (4%)
Weight (kg) 32·0 (17·7) 31·8 (18·2) 22·4 (11·9) 21·9 (12·2) 27·2 (13·8) 26·5 (13·7) 23·1 (12·1) 22·5 (11·2)
Weight group (kg)
<20 213 (32%) 233 (35%) 359 (54%) 366 (55%) 161 (36%) 171 (38%) 447 (50%) 457 (51%)
≥20 460 (68%) 438 (65%) 310 (46%) 302 (45%) 287 (64%) 277 (62%) 445 (50%) 434 (49%)
Fever present 434 (64%) 397 (59%) 315 (47%) 360 (54%) 263 (59%) 265 (59%) 478 (54%) 497 (56%)
Body temperature (°C) 37·9 (1·1) 37·8 (1·1) 37·5 (1·1) 37·6 (1·0) 37·8 (1·1) 37·9 (1·1) 37·7 (1·1) 37·7 (1·1)
Plasmodium falciparum 
asexual forms
665 (99%) 663 (99%) 646 (97%) 652 (98%) 440 (98%) 443 (99%) 867 (97%) 869 (98%)
Median number of 
parasites per µL (IQR)
20 560 
(4820–55 060)
24 860 
(5380–56 620)
12 310 
(1160–48 080)
17 100 
(1170–50 140)
22 370 
(4050–55 680)
23 940 
(3278–56 980)
13 060 
(1200–38 380)
15 360 
(1020–43 520)
Plasmodium ovale 
asexual forms,
2 (<1%) 5 (<1%) 3 (<1%) 6 (<1%) 0 4 (<1%) 8 (<1%) 11 (1%)
Median number of 
parasites per µL (IQR)
2840 
(2120–3560)
312 
(120–4200)
1300 
(80–4160)
1370 
(480–2240)
0 1380 
(350–3020)
1520 
(460–2700)
480 
(96–2260)
Plasmodium malariae 
asexual forms
15 (2%) 19 (3%) 36 (5%) 27 (4%) 15 (3%) 7 (2%) 46 (5%) 45 (5%)
Median parasite 
density per µL (IQR)
660 
(100–2140)
540 
(200–1420)
900 
(312–2450)
1240 
(560–4380)
800 
(128–2040)
1900 
(440–2240)
830 
(400–3680)
960 
(192–3720)
Patients with gametocytes
P falciparum 13 (2%) 14 (2%) 16 (2%) 29 (4%) 15 (3%) 19 (4%) 21 (2%) 29 (3%)
P ovale 1 (<1%) 0 0 1 (<1%) 0 1 (<1%) 0 1 (<1%)
P malariae 1 (<1%) 0 3 (<1%) 2 (<1%) 5 (1%) 5 (1%) 0 1 (<1%)
Data are n (%) or mean (SD), unless stated otherwise. 152 patients receiving artemether–lumefantrine and 498 receiving artesunate–amodiaquine were randomly assigned to both pyronaridine–artesunate and 
dihydroartemisinin–piperaquine and so were included in both separate comparisons (figure 1).
Table 1: Baseline demographic and clinical characteristics at the first uncomplicated malaria episode (in the intention-to-treat and safety population)
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(38·1%, 95% CI 34·3–41·8) for pyronaridine–artesunate 
versus 189/663 (29·0%, 25·0–31·9) for artemether–
lumefantrine; appendix). P falciparum gam eto cytes were 
detected in 134 (3%) of 4606 patients at study enrolment, 
but data were too sparse to compare clearance rates.
For all uncomplicated Plasmodium spp malaria 
episodes, bronchitis and rhinitis were the most frequent 
adverse events of any cause across all treatment 
groups (table 2). There was no increase in the incidence 
of adverse events on repeated treatment for any 
study drug (appendix). Adverse events were more 
common in patients younger than 5 years and those with 
bodyweight less than 20 kg across all treatment groups, 
but there was no increase in the incidence of adverse 
Figure 2: Treatment efficacy comparisons
Data are for A) pyronaridine–artesunate versus comparators and B) dihydroartemisinin–piperaquine versus comparators. Forest plots are for the primary efficacy 
endpoints of 2-year incidence of Plasmodium spp malaria (uncomplicated and complicated), estimated using negative binomial regression in the intention-to-treat 
(ITT) population and the difference in adequate clinical and parasitological response (ACPR) across all P falciparum uncomplicated malaria episodes, estimated using a 
generalised estimating equation (in the per-protocol population). Kaplan-Meier estimates are shown for the time to P falciparum recurrence following treatment of 
the first malaria episode (in the ITT population). PA=pyronaridine–artesunate. AL=artemether–lumefantrine. ASAQ=artesunate–amodiaquine. 
DP=dihydroartemisinin–piperaquine. P falciparum=Plasmodium falciparum. *Based on raw incidence rate (not generalised estimating equation model) as ACPR was 
100% in the dihydroartemisinin–piperaquine group.
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events on repeated treatment (appendix). Most adverse 
events were of mild to moderate severity (appendix). 
Drug-related adverse events are in the appendix.
There were nine deaths during the study, none of which 
were related to study treatment (appendix). Serious 
adverse events were uncommon and occurred mainly 
during the first malaria episode (table 2, appendix). Drug-
related serious adverse events were associated mainly 
with increases in liver enzymes (appendix).
Mostly mild transient increases in liver enzymes 
occurred with pyronaridine–artesunate, which did not 
worsen on retreatment (appendix; table 2, figure 3). 
The incidence of hepatotoxicity events (defined as 
ALT >5 × ULN or Hy’s criteria: ALT or AST >3 × ULN 
and total bilirubin >2 × ULN) was 15 patients 
(2%) of 662 for pyronaridine–artesunate versus 
four (<1%) of 665 for artemether–lumefantrine, and 
seven (1%) of 661 for pyro naridine–artesunate versus 
four (<1%) of 659 for arte sunate–amodiaquine (appendix). 
Hepato toxicity events with pyronaridine–artesunate were 
more common in adults (five [4%] of 123) than in children 
younger than 5 years (seven [2%] of 332) or aged 5 to 
younger than 18 years (ten [1%] of 868), and more 
common in patients weighing at least 20 kg (14 [2%] of 765) 
than in patients less than 20 kg (eight [1%] of 558; 
appendix). None of the hepatotox icity events were 
associated with any signs or symptoms, required any 
intervention, or resulted in any sequelae.
Exclusions from repeated treatment owing to hepa-
toxicity events occurred in five (<1%) of 662 patients 
with pyronaridine–artesunate versus seven (1%) of 
665 with artemether–lumefantrine; one (<1%) of 661 with 
pyronari dine–artesunate versus eight (1%) of 659 with 
artesunate–amodiaquine; five (1%) of 440 with dihydro-
artemisinin–piperaquine versus nine (2%) with arte-
mether–lumefantrine; and four (<1%) of 885 with 
dihydro artemisinin–piperaquine versus 11 (1%) of 
884 with artesunate–amodiaquine (appendix). Inadvertent 
redosing following hepatotoxicity events occurred in nine 
patients treated with pyronaridine–artesunate, three with 
artemether–lumefantrine, four with artesunate–amo-
diaquine, and two with dihydroartemisinin–piper aquine, 
but resulted in no clinical symptoms, worsening of liver 
function tests, or exacerbation of hepatotoxicity.
Overall, potential Hy’s law cases occurred in three 
patients (0·22%) of 1342 receiving pyronaridine–artesunate, 
three (0·31%) of 967 receiving artemether–lumefantrine, 
one (0·09%) of 1061 receiving artesunate–amodiaquine, 
and two (0·15%) of 1340 receiving dihydroartemisinin–
piperaquine (figure 3, appendix). Alkaline phosphatase 
was high in one patient receiving pyronaridine–artesunate 
and two receiving artemether–lumefantrine (appendix). 
Pyronaridine–artesunate versus 
artemether–lumefantrine
Pyronaridine–artesunate versus 
artesunate–amodiaquine
Dihydroartemisinin–piperaquine versus 
artemether–lumefantrine
Dihydroartemisinin–piperaquine 
versus artesunate–amodiaquine
Pyronaridine–
artesunate 
(n=673)
Artemether–
lumefantrine 
(n=671)
Pyronaridine–
artesunate 
(n=669)
Artesunate–
amodiaquine 
(n=668)
Dihydroartemisinin–
piperaquine (n=448)
Artemether–
lumefantrine 
(n=448)
Dihydroartemisinin–
piperaquine (n=892)
Artesunate–
amodiaquine 
(n=891)
Any adverse event 373 (55%) 411 (61%) 364 (54%) 391 (59%) 242 (54%) 226 (50%) 448 (50%) 406 (46%)
Any drug-related 
adverse event
203 (30%) 220 (33%) 138 (21%) 209 (31%) 142 (32%) 99 (22%) 205 (23%) 205 (23%)
Serious adverse events 13 (2%) 9 (1%) 10 (1%) 6 (<1%) 1 (<1%) 1 (<1%) 11 (1%) 5 (<1%)
Serious drug-related 
adverse events
3 (<1%) 2 (<1%) 4 (<1%) 2 (<1%) 1 (<1%) 0 4 (<1%) 1 (<1%)
Adverse events by preferred term
Anaemia 33 (5%) 35 (5%) 15 (2%) 8 (1%) 31 (7%) 31 (7%) 11 (1%) 5 (<1%)
Monocytosis 13 (2%) 12 (2%) 0 0 22 (5%) 28 (6%) 0 0
Neutropenia 56 (8%) 64 (10%) 0 0 67 (15%) 71 (16%) 0 0
Abdominal pain 23 (3%) 25 (4%) 35 (5%) 37 (6%) 18 (4%) 16 (4%) 53 (6%) 53 (6%)
Vomiting 23 (3%) 17 (3%) 38 (6%) 58 (9%) 12 (3%) 6 (1%) 58 (7%) 82 (9%)
Bronchitis 115 (17%) 146 (22%) 156 (23%) 142 (21%) 101 (23%) 118 (26%) 179 (20%) 172 (19%)
Rhinitis 100 (15%) 103 (15%) 112 (17%) 110 (16%) 79 (18%) 67 (15%) 105 (12%) 135 (15%)
ALT increased 35 (5%) 11 (2%) 11 (2%) 4 (<1%) 6 (1%) 9 (2%) 13 (1%) 12 (1%)
AST increased 40 (6%) 17 (3%) 13 (2%) 6 (<1%) 8 (2%) 10 (2%) 13 (1%) 17 (2%)
QT prolonged 55 (8%) 99 (15%) 34 (5%) 91 (14%) 71 (16%) 36 (8%) 251 (28%) 195 (22%)
Abnormal ECG 4 (<1%) 4 (<1%) 0 0 29 (6%) 11 (2%) 0 0
Hypercreatininaemia 46 (7%) 51 (8%) 1 (<1%) 2 (<1%) 61 (14%) 55 (12%) 1 (<1%) 2 (<1%)
Headache 9 (1%) 12 (2%) 15 (2%) 14 (2%) 7 (2%) 9 (2%) 42 (5%) 45 (5%)
Cough 40 (6%) 42 (6%) 56 (8%) 54 (8%) 36 (8%) 34 (8%) 95 (11%) 108 (12%)
Data are n (%) of patients for events occurring in at least 5% of patients in any one treatment group. ALT=alanine aminotransferase. AST=aspartate aminotransferase. ECG=electrocardiogram.
Table 2: All-cause adverse events across all uncomplicated malaria episodes treated with study drugs (safety population)
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Seven of the nine potential Hy’s law cases occurred 
during the first treatment episode, and all cases resolved 
spontaneously without treatment or sequelae. There were 
no other notable differences between treatment groups in 
key haematological or biochemical laboratory measures 
(appendix).
Across all episodes, QTcF prolongation of more than 
60 ms versus baseline occurred more frequently with 
dihydroartemisinin–piperaquine (31 patients [11%] of 288) 
than artemether–lumefantrine (five [3%] of 199), but in a 
similar proportion of patients for dihydro artemisinin–
piperaquine (55 [11%] of 509) versus artesunate–
amodiaquine (50 [12%] of 433; appendix). Overall, 
six patients (<1%) of 797 receiving dihydro artemisinin–
piperaquine had any post-dose QTcF value longer 
than 500 ms (appendix). Although there were few data 
from retreatment episodes (68 for dihydroartemisinin–
piper aquine vs 95 for artesunate–amodiaquine), there 
was no evidence that QTcF prolongation was more 
frequent following malaria retreatment (appendix). There 
was a trend for more frequent QTcF prolongation 
with dihydroartemisinin–piperaquine in patients aged 
5–18 years than in adults or children younger than 5 years, 
but no difference based on bodyweight category (appendix). 
QTcF prolongation of more than 60 ms versus baseline 
was less frequent with pyronaridine–artesunate (in 
nine patients [2%] of 493) versus artemether–lumefantrine 
(12 [3%] of 400) and for pyronaridine–artesunate 
(three [2%] of 140) versus artesunate–amodiaquine 
(14 [12%] of 117; appendix). Overall, 226 patients (9%) of 
2579 patients were excluded from repeated treatment 
because of QTcF prolongation (appendix).
Figure 3: Liver enzyme concentrations during the study
Data are (A) peak alanine aminotransferase (ALT) concentrations versus total bilirubin concentration and (B) peak aspartate aminotransferase (AST) concentrations 
versus total bilirubin concentration. All available data after antimalarial drug treatment from day 3 until the end of observation following treatment of a 
first malaria episode or any uncomplicated malaria retreatment episode in the safety population. ULRR=upper limit of reference range. 
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Discussion
All treatment regimens tested in this study were highly 
efficacious and well tolerated in repeated treatment 
over 2 years. All study treatments had more than 
99% efficacy in the PCR-adjusted PP population at 
days 28 and 42, similar to findings from previous studies 
in the region (>96% day 28 ACPR).3,5 Analysis of 
P falciparum isolates obtained in this study from patients 
in Mali showed decreased susceptibility to both 
artemether and lumefantrine.31 Although there was no 
effect on clinical efficacy, these findings highlight the 
potential risks of using a single ACT. Further 
investigations are ongoing, including plasmepsin 2 and 
plasmepsin 3 copy number and exonuclease 
polymorphisms as molecular markers of piperaquine 
resistance.32
Malaria incidence was high in the study area and most 
patients had at least two malaria episodes during the study. 
Repeated malaria is particularly concerning in young 
children, as it might affect their normal development, and 
the economic costs to families of frequent malaria episodes 
is substantial. For the first time, we showed the benefit of 
dihydroartemisinin–piperaquine on reducing 2-year 
Plasmodium spp malaria incidence rate following repeated 
treatment. This improvement might be explained by the 
long piperaquine half-life of around 4 weeks providing 
post-treatment prophylaxis.33 However, this long half-life 
might also increase the risk of resistance selection.34 In 
Cambodia and elsewhere in the Greater Mekong 
subregion, the emergence and spread of parasites resistant 
to both artemisinin and piperaquine has been rapid and 
profound, with high clinical failure rates.35,36 Thus, 
widespread adoption of dihydroartemisinin–piperaquine 
in west Africa should be approached cautiously with 
assessment of treatment efficacy and monitoring of 
molecular markers of artemisinin and piperaquine 
resistance.32
Pyronaridine–artesunate has a terminal half-life of at 
least 13 days, compared with around 8–10 days for 
amodiaquine and 4 days for lumefantrine. The observed 
results for unadjusted ACPR and the risk of recurrence 
are thus consistent with the half-lives of the drugs, with 
pyronaridine–artesunate intermediate between dihydro-
artemisinin–piperaquine and artemether–lumefantrine. 
The 2-year Plasmodium spp malaria incidence rate 
for pyronaridine–artesunate was non-inferior to 
comparators, but there was no apparent effect of the 
limited post-treatment prophylaxis with pyronaridine–
artesunate on reducing the malaria incidence rate versus 
comparators. We hypothesise that, as many factors 
contribute to malaria incidence rate, a longer period of 
post-treatment prophylaxis is needed to affect this 
outcome, as was noted with dihydroartemisinin–
piperaquine. There is no evidence that historical 
pyronaridine monotherapy use has led to resistance 
emergence in Asia, though clinical efficacy of 
pyronaridine–artesunate in western Cambodia is lower 
than elsewhere in the region.12,37 Consequently, there 
is currently no validated molecular marker for pyro-
naridine resistance.
Safety outcomes for malaria retreatment were consistent 
with the known safety profiles of the four ACTs.3–5,9–21 
Consistent with the interim analysis,14 this larger dataset 
indicated no increased risk of liver injury on pyronaridine–
artesunate retreatment.9 Although pyronaridine–
artesunate caused transient mild increased liver 
transaminases, the incidence of potential Hy’s law events 
seemed to be low and no greater than with artemether–
lumefantrine.9,10,13,14 Although careful monitoring for liver 
enzyme increases was specified in the protocol, 
management of such a large study made this practically 
challenging and some patients with hepatotoxicity events 
on first treatment were retreated. None of these patients 
had hepatotoxicity events on repeated treatment. None of 
the patients with hepatic enzyme elevations had any 
clinical symptoms, required any intervention, or 
experienced sequelae.
The incidence of QTcF prolongation was higher 
following dihydroartemisinin–piperaquine versus com-
parators, although this was without clinical symptoms. 
This finding is consistent with those from a study in 
African patients after single treatment of uncomplicated 
malaria.38 In the current study, QTcF prolongation also 
occurred with artesunate–amodiaquine. The incidence 
of QTcF prolongation did not appear to change on 
malaria retreatment, although there were few data for 
this outcome. Further analyses will examine the effect of 
the four ACTs on QTc interval during the first malaria 
episode (Cardiabase, Nancy, France).
This was a large and complex longitudinal study with 
several protocol amendments. The trial also required an 
amendment in design because of the outbreak of Ebola 
virus disease in west Africa from 2014 to 2016. Although 
this amendment was efficient in terms of 
time and resources, it increased complexity and the 
throughput of patients at the trial sites. One important 
caveat regarding the safety conclusions is that participants 
with pre-existing QTc prolongation or increased liver 
enzymes were excluded from the study. Additionally, 
participants with these adverse events occurring during 
the follow-up period for each episode were excluded. 
Thus, as is the case for all clinical trials, the safety data 
reported here reflect a selected population and careful 
pharmacovigilance will be needed to assess study drug 
safety in individuals potentially most at risk of these 
specific adverse events.
In many west African countries, artemether–
lumefantrine is the only first-line ACT used. This is a 
fragile situation for a region which accounts for around 
half the world’s malaria deaths, and reports of emerging 
artemether–lumefantrine resistance are concerning.39,40 
This study showed non-inferior efficacy and acceptable 
safety for both pyronaridine–artesunate and dihydro-
artemisinin–piperaquine for retreatment of uncomplicated 
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malaria in African populations compared with artemether–
lumefantrine and artesunate–amodiaquine, and therefore 
pyronaridine–artesunate and dihydroartemisinin–piper-
aquine should be considered for diversifying ACT use 
across the region.
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